Endometrial cancer of the very elderly: Management and survival in the Francogyn population

Archive ouverte

Martin, Flore-Anne | Dion, Ludivine | Nyangoh Timoh, Krystel | Dupré, Pierre François | Azaïs, Henri | Bendifallah, Sofiane | Touboul, Cyril | Dabi, Yohann | Graesslin, Olivier | Raimond, Emilie | Costaz, Hélène | Kerbage, Yohan | Huchon, Cyrille | Mimoun, Camille | Koskas, Martin | Akladios, Cherif | Lecointre, Lise | Canlorbe, Geoffroy | Chauvet, Pauline | Ouldamer, Lobna | Levêque, Jean | Lavoué, Vincent

Edité par CCSD ; WB Saunders -

International audience. Introduction - We aimed to describe management and survival of patients with endometrial cancer (EC) ≥80 years to identify poor prognosis criteria. Methods - We collected clinical, histologic, surgical and follow-up data for patients with EC ≥ 80 years included in a multicenter French cohort (FRANCOGYN) who underwent primary surgical treatment from 1999 to 2019. The outcomes were overall survival (OS) and disease-free survival (DFS). We performed a descriptive analysis then a survival time analysis and comparison using the Kaplan Meier method and log-rank test. Results - Of the 1647 patients with EC who received treatment during the study period, 184 (11.17%) were ≥80 years. The mean age was 84 years (±3.34). Thirty-three patients (25.4%) died during the follow-up period and 26 relapsed (18.4%). Forty-nine patients were lost to follow-up (27.37%). The median follow-up time was 15.3 months (4.9-28.8). The median OS and DFS was 16.4 months (6.3-24.9) and 13.6 months (4.5-26.6), respectively. Eighty-three patients received adjuvant therapy (45.11%), out of 95 who had a formal or relative indication. Four patients received adjuvant chemotherapy (2.6%), out of 61 who had a formal or relative indication. Inappropriate or underuse of chemotherapy was significantly associated with a lower median OS of 12.6 months [3.73-24] versus 17.3 months [7.93-41.77] when performed appropriately (HR = 4.14, CI 95% [1.62-10.56]), and a lower median DFS of 10.83 months [3.73-24] versus 17.3 months [7.93-28.5] (HR = 9.04, CI 95% [2.04-40.12]). Conclusion - Our results suggest that very elderly patients with EC should receive adjuvant chemotherapy according to the standard care guidelines.

Suggestions

Du même auteur

Impact of severe obesity in the management of patients with high-risk endometrial cancer: A FRANCOGYN study

Archive ouverte | Simon, Ombline | CCSD

International audience. Objective: To assess the surgical management and survival of severely obese patients with high-risk endometrial cancer.Materials and methods: Data from 269 patients with high-risk endometrial...

Ovarian Cancer in the Elderly Time to Move towards a More Logical Approach to Improve Prognosis-A Study from the FRANCOGYN Group

Archive ouverte | Dion, Ludivine | CCSD

International audience. Background and objective: Elderly and/or frail women with ovarian cancer are often undertreated. The aim of the study is to compare the effects of age and frailty on surgical approaches, post...

Management and Survival of Elderly and Very Elderly Patients with Ovarian Cancer An Age-Stratified Study of 1123 Women from the FRANCOGYN Group

Archive ouverte | Joueidi, Yolaine | CCSD

International audience. Elderly women with ovarian cancer are often undertreated due to a perception of frailty. We aimed to evaluate the management of young, elderly and very elderly patients and its impact on surv...

Chargement des enrichissements...